These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 28034904)

  • 41. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
    Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC
    Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
    Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
    Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
    Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
    BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Sensitization of Triple-Negative Breast Cancers to Poly ADP Ribose Polymerase Inhibition Independent of BRCA1/2 Mutation Status by Chemically Modified microRNA-489.
    Soung YH; Ju J; Chung J
    Cells; 2023 Dec; 13(1):. PubMed ID: 38201253
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
    Castroviejo-Bermejo M; Cruz C; Llop-Guevara A; Gutiérrez-Enríquez S; Ducy M; Ibrahim YH; Gris-Oliver A; Pellegrino B; Bruna A; Guzmán M; Rodríguez O; Grueso J; Bonache S; Moles-Fernández A; Villacampa G; Viaplana C; Gómez P; Vidal M; Peg V; Serres-Créixams X; Dellaire G; Simard J; Nuciforo P; Rubio IT; Dienstmann R; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Déas O; Jonkers J; Masson JY; Cairo S; Judde JG; O'Connor MJ; Díez O; Balmaña J; Serra V
    EMBO Mol Med; 2018 Dec; 10(12):. PubMed ID: 30377213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.
    Mukhopadhyay A; Elattar A; Cerbinskaite A; Wilkinson SJ; Drew Y; Kyle S; Los G; Hostomsky Z; Edmondson RJ; Curtin NJ
    Clin Cancer Res; 2010 Apr; 16(8):2344-51. PubMed ID: 20371688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 50. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
    Chopra N; Tovey H; Pearson A; Cutts R; Toms C; Proszek P; Hubank M; Dowsett M; Dodson A; Daley F; Kriplani D; Gevensleben H; Davies HR; Degasperi A; Roylance R; Chan S; Tutt A; Skene A; Evans A; Bliss JM; Nik-Zainal S; Turner NC
    Nat Commun; 2020 May; 11(1):2662. PubMed ID: 32471999
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer.
    Mu C; Wu X; Zhou X; Wolfram J; Shen J; Zhang D; Mai J; Xia X; Holder AM; Ferrari M; Liu X; Shen H
    Clin Cancer Res; 2018 Oct; 24(19):4900-4912. PubMed ID: 29921732
    [No Abstract]   [Full Text] [Related]  

  • 53. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
    Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
    Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modeling Therapy Resistance in
    Dréan A; Williamson CT; Brough R; Brandsma I; Menon M; Konde A; Garcia-Murillas I; Pemberton HN; Frankum J; Rafiq R; Badham N; Campbell J; Gulati A; Turner NC; Pettitt SJ; Ashworth A; Lord CJ
    Mol Cancer Ther; 2017 Sep; 16(9):2022-2034. PubMed ID: 28619759
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
    Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
    Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
    [No Abstract]   [Full Text] [Related]  

  • 56. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
    Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
    Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
    Holme H; Gulati A; Brough R; Fleuren EDG; Bajrami I; Campbell J; Chong IY; Costa-Cabral S; Elliott R; Fenton T; Frankum J; Jones SE; Menon M; Miller R; Pemberton HN; Postel-Vinay S; Rafiq R; Selfe JL; von Kriegsheim A; Munoz AG; Rodriguez J; Shipley J; van der Graaf WTA; Williamson CT; Ryan CJ; Pettitt S; Ashworth A; Strauss SJ; Lord CJ
    Sci Rep; 2018 Jul; 8(1):10614. PubMed ID: 30006631
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 59. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
    Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
    J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
    Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
    Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.